New 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidine (PMEO-DAPy) and 1-[2-(phosphonomethoxy)ethyl]-5-azacytosine (PME-5-azaC) prodrugs were prepared with a pro-moiety consisting of carbonyloxymethyl esters (POM, POC), alkoxyalkyl esters, amino acid phosphoramidates and/or tyrosine. The activity of the prodrugs was evaluated in vitro against different virus families. None of the synthesized prodrugs demonstrated activity against RNA viruses but some of them proved active against herpesviruses [including herpes simplex virus (HSV), varicella-zoster virus (VZV), and human cytomegalovirus (HCMV)]. The bis(POC) and the bis(amino acid) phosphoramidate prodrugs of PMEO-DAPy inhibited herpesvirus replication at lower doses than the parent compound although the selectivity against HSV and VZV was only slightly improved compared to PMEO-DAPy. The mono-octadecyl ester of PME-5-azaC emerged as the most potent and selective PME-5-azaC prodrug against HSV, VZV and HCMV with EC50's of 0.15-1.12µM while PME-5-azaC only had marginal anti-herpesvirus activity. Although the bis(hexadecylamido-l-tyrosyl) and the bis(POM) esters of PME-5-azaC were also very potent anti-herpesvirus drugs, these were less selective than the mono-octadecyl ester prodrug.

Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Flemingovo nám 2 CZ 166 10 Prague 6 Czech Republic

Rega Institute for Medical Research KU Leuven Herestraat 49 Box 1043 B 3000 Leuven Belgium

See more in PubMed

Holý A. Curr Pharm Des. 2003;9:2567. PubMed

De Clercq E., Holý A. Nat Rev Drug Disc. 2005;4:928. PubMed

De Clercq E. Biochem Pharmacol. 2011;82:99. PubMed

De Clercq E. Med Res Rev. 2012;32:765. PubMed

De Clercq E. Med Res Rev. 2009;29:571. PubMed

Balzarini J., Holý A., Jindřich J., et al. Proc Nat Acad Sci USA. 1991;88:4961. PubMed PMC

Krečmerová M., Holý A., Pískala A., et al. J Med Chem. 2007;1069:50. PubMed

Holý A., Votruba I., Masojídková M., et al. J Med Chem. 2002;45:1918. PubMed

Balzarini J., Pannecouque C., De Clercq E., et al. Antimicrob Agents Chemother. 2002;46:2185. PubMed PMC

Hocková D., Holý A., Masojídková M., et al. J Med Chem. 2003;46:5064. PubMed

Dvořáková H., Holý A. Collect Czech Chem Commun. 1993;58:1419.

Herman B.D., Votruba I., Holý A., Sluis-Cremer N., Balzarini J. J Biol Chem. 2010;285:12101. PubMed PMC

Krečmerová M., Otmar M. Future Med Chem. 2012;4:991. PubMed

Krečmerová M., Holý A., Pohl R., et al. J Med Chem. 2007;50:5765. PubMed

Dračínský M., Krečmerová M., Holý A. Bioorg Med Chem. 2008;16:6778. PubMed

Wyles D.L., Kaihara K.A., Korba B.E., Schooley R.T., Beadle J.R., Hostetler K.Y. Antimicrob Agents Chemother. 2009;53:2660. PubMed PMC

McMullan L.K., Flint M., Dyall J., et al. Antiviral Res. 2016;125:71. PubMed

Starrett J.E., Jr., Tortolani D.R., Russell J., et al. J Med Chem. 1994;37:4857. PubMed

Jansa P., Baszczyňski O., Dračínský M., et al. Eur J Med Chem. 2011;46:3748. PubMed

Mehellou Y., Balzarini J., McGuigan C. ChemMedChem. 2009;4:1779. PubMed

Hostetler K.Y. Antiviral Res. 2009;82:A84. PubMed PMC

http://www.chimerix.com/research-development/clinical-trials/.

Krečmerová M., Holý A., Andrei G., et al. J Med Chem. 2010;53:6825. PubMed

Peterson L.W., Kim J.S., Kijek P., et al. Bioorg Med Chem Lett. 2011;21:4045. PubMed PMC

Zakharova V.M., Serpi M., Krylov I.S., et al. J Med Chem. 2011;54:5680. PubMed PMC

Krylov I.S., Kashemirov B.A., Hilfinger J.M., McKenna C.E. Mol Pharm. 2013;10:445–458. PubMed PMC

Holý A., Günter J., Dvořáková H., et al. J Med Chem. 1999;42:2064. PubMed

Vrbková S., Dračinský M., Holý A. Tetrahedron. 2007;63:11391.

Gruber B., Balk S., Stadlbauer S., König S. Angew Chem Int Ed. 2012;124:10207. PubMed

Phosphonates and Phosphonate Prodrugs in Medicinal Chemistry: Past Successes and Future Prospects

Synthesis of fluorinated acyclic nucleoside phosphonates with 5-azacytosine base moiety